Chronic Macrolide Therapy in Inflammatory Airways Diseases
Chronic Macrolide Therapy in Inflammatory Airways Diseases
复制标题
DOI：
10.1378/chest.10-0196
复制
发表时间：
2010-11-01
期刊：
影响因子：
9.6
通讯作者：
Albert, Richard K.
中科院分区：
文献类型：
--
作者：
Friedlander, Adam L.;Albert, Richard K.
在20世纪80年代后期，大环内酯类抗生素红霉素的长期治疗被证明可以改变弥漫性泛细支气管炎的临床病程。从那时起，发现大环内酯类除了作为抗微生物剂之外，还具有大量的抗微生物特性。这些观察结果为过去十年中进行的许多研究提供了依据，以评估大环内酯类药物在其他炎性气道疾病（如囊性纤维化、哮喘、COPD和闭塞性细支气管炎综合征）中的有效性。本文综述了大环内酯类药物的免疫调节特性，以及这些最近的研究结果表明其作为疾病修饰剂的潜力。胸部2010; 138（5）：1202-1212
Long-term therapy with the macrolide antibiotic erythromycin was shown to alter the clinical course of diffuse panbronchiolitis in the late 1980s. Since that time, macrolides have been found to have a large number of antiinflammatory properties in addition to being antimicrobials. These observations provided the rationale for many studies performed over the last decade to assess the usefulness of macrolides in other inflammatory airways diseases, such as cystic fibrosis, asthma, COPD, and bronchiolitis obliterans syndrome. This review summarizes the immunomodulatory properties of macrolides and the results of these recent studies demonstrating their potential for being disease-modifying agents. CHEST 2010; 138(5):1202-1212